地中海贫血所致骨质疏松症患者停用唑来膦酸两年后骨矿物质密度持续改善：一项随机、安慰剂对照试验的长期随访 - Suppr

Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial.

作者信息

Voskaridou Ersi, Christoulas Dimitrios, Konstantinidou Marialena, Tsiftsakis Evangelos, Alexakos Panagiotis, Terpos Evangelos

出版信息

Haematologica. 2008 Oct;93(10):1588-90. doi: 10.3324/haematol.12849. Epub 2008 Aug 12.

DOI:10.3324/haematol.12849

PMID:18698086

Abstract

摘要

相似文献

Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial.

Haematologica. 2008 Oct;93(10):1588-90. doi: 10.3324/haematol.12849. Epub 2008 Aug 12.

Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis.

Acta Haematol. 2008;119(1):40-4. doi: 10.1159/000114869. Epub 2008 Feb 5.

Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial.

Ann Hematol. 2006 Sep;85(9):605-9. doi: 10.1007/s00277-006-0136-y. Epub 2006 Jul 8.

Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.

Ann Hematol. 2007 Jan;86(1):23-30. doi: 10.1007/s00277-006-0180-7. Epub 2006 Sep 30.

Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis.

Ann Hematol. 2008 Nov;87(11):947-8. doi: 10.1007/s00277-008-0497-5. Epub 2008 Apr 29.

Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration.

Haematologica. 2009 May;94(5):725-8. doi: 10.3324/haema-tol.2008.000893.

Taurine deficiency in thalassemia major-induced osteoporosis treated with neridronate.

Biomed Pharmacother. 2010 Apr;64(4):271-4. doi: 10.1016/j.biopha.2009.06.014. Epub 2009 Oct 23.

[Prostatic carcinoma. Zoledronic acid raises bone density].

Aktuelle Urol. 2003 Dec;34(7):424. doi: 10.1055/s-2003-814720.

Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF).

Clin Endocrinol (Oxf). 2009 Jun;70(6):838-46. doi: 10.1111/j.1365-2265.2008.03434.x. Epub 2008 Sep 24.

Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial.

Haematologica. 2006 Sep;91(9):1193-202.

引用本文的文献

Aetiology, diagnosis and treatment of thalassemia-associated osteoporosis of the adult.

J Endocrinol Invest. 2025 Apr;48(4):799-815. doi: 10.1007/s40618-024-02503-2. Epub 2025 Jan 6.

Recent advancements in glucose dysregulation and pharmacological management of osteoporosis in transfusion-dependent thalassemia (TDT): an update of ICET-A (International Network of Clinicians for Endocrinopathies in Thalassemia and Adolescence Medicine).

Acta Biomed. 2023 Jun 14;94(3):e2023178. doi: 10.23750/abm.v94i3.14805.

Treatment for osteoporosis in people with beta-thalassaemia.

Cochrane Database Syst Rev. 2023 May 9;5(5):CD010429. doi: 10.1002/14651858.CD010429.pub3.

Approach to the management of β thalassemia major associated osteoporosis - A long-standing relationship revisited.

Acta Biomed. 2022 Oct 26;93(5):e2022305. doi: 10.23750/abm.v93i5.13668.

Comparative effectiveness of alendronate and zoledronic acid on bone mass improvement in transfusion-dependent thalassemia patients.

J Bone Miner Metab. 2019 Nov;37(6):996-1003. doi: 10.1007/s00774-019-01003-1. Epub 2019 Apr 11.

Zoledronic Acid for Treatment of Low Bone Mineral Density in Patients with Beta Thalassemia Major.

Indian J Hematol Blood Transfus. 2018 Oct;34(4):648-652. doi: 10.1007/s12288-018-0953-x. Epub 2018 Mar 27.

Safety of Zoledronic Acid in Patients with Thalassemia Associated Low Bone Mineral Density.

Indian J Hematol Blood Transfus. 2018 Apr;34(2):345-346. doi: 10.1007/s12288-017-0858-0. Epub 2017 Aug 9.

Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease.

Osteoporos Int. 2016 Dec;27(12):3409-3425. doi: 10.1007/s00198-016-3719-z. Epub 2016 Aug 8.

Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials.

J Bone Miner Metab. 2014 Nov;32(6):606-15. doi: 10.1007/s00774-014-0584-8. Epub 2014 Apr 21.

Osteoporosis in young adults: pathophysiology, diagnosis, and management.

Osteoporos Int. 2012 Dec;23(12):2735-48. doi: 10.1007/s00198-012-2030-x. Epub 2012 Jun 9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial.

作者信息

出版信息

相似文献

引用本文的文献